Abstract #3737: A highly potent, selective and orally available ALK inhibitor with demonstrated antitumor efficacy in ALK dependent lymphoma and non small cell lung cancer models

Elena Ardini, Arturo Galvani, Cristina Ponti et al.|Cancer Research|2009

Cited by 0